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Introduction 
The importance of the relationship between bacteria and the pathogenesis 
of pulpal and periradicular disease has been well established by numerous 
studies (Kakehashi et ai, 1965; Sundqvist, 1976; Patterson, 1976; Moller, 1981). 
Pulpal infections initially produce an inflammatory response within the pulp that 
often leads to complete pulpal necrosis and subsequently, in the periapical 
region, which results in lesion formation with local bone destruction (Bergenholtz, 
1990). The bacteria from infected root canals have been extensively studied and 
shown to be predominantly gram-negative and strictly anaerobic (Fabricius, 
1982; Farber and Seltzer, 1988). Bacterial lipopolysaccharide (LPS) is an 
endotoxin and a major component of the outer membrane of gram-negative 
bacteria. It is a complex glycolipid composed of a hydrophilic polysaccharide 
moiety and a hydrophobic domain known as Lipid A. It is also one of the most 
potent microbial initiators of inflammation (Raetz, 1990; Cohen 2002) and 
endodontic pathogenesis (Dwyer and Torabinejad, 1981). A positive correlation 
has been reported between the levels of LPS in root canals and the presence of 
periapical lesions (Dahlen and Bergenholtz, 1980; Schonfeld et a/1982). 
Cells of the host's immune response system may detect and respond to 
bacteria and their byproducts. Although these products have structural 
sequences that are unique to strain and species specific variations, they also 
have a highly conserved and common molecular pattern that does not vary 
between microbes. This is called the pathogen associated molecular pattern 
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(PAMP) (Janeway, 1989). LPS represents the PAMP in gram-negative bacteria 
and the Lipid A segment is the invariant portion that is responsible for its pro-
inflammatory effects. Host immune cells recognize PAMP through a family of 
proteins known as Toll-like receptors (TLRs) which are an essential part of the 
recognition and signaling component of the mammalian host defense system 
(Akira, 2001). Human TLR4 was the first TLR to be described. It is 
predominantly expressed in immune cells, and has now been established as the 
receptor for LPS (Medzhitov et aI, 1997). Once LPS passes through the apical 
foramen and into the periradicular tissue where it binds its receptor, it starts a 
cascade that leads to NF-kB activation of numerous inflammatory genes that 
result in cytokine production, which subsequently initiate and sustain many of the 
bone osteolytic events in endodontic disease (Stashenko, 1998). It has been 
shown that LPS can directly stimulate osteoblasts to express RANKL, resulting in 
osteoclast formation (Kikuchi et aI, 2001). Recent findings have also indicated 
that LPS may be directly involved in osteoclast differentiation (Suda et al., 2002; 
Jiang et al., 2006). NFATc1 has been shown to be a key regulator of 
osteoclastogenesis and plays a critical role in the terminal differentiation of 
osteoclasts (Takayanagi et al., 2002). Once differentiated and activated, mature 
osteoclasts can act to resorb bone in this specialized microenvironment resulting 
in apical lesion formation (Dahlen, 1981). 
Researchers have identified a series of cytokines that are produced by 
both inflammatory and non-inflammatory host cells that are involved in the bone 
resorptive process (Stashenko, 1994; Fouad, 1997; Stashenko, 1998). These 
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cytokines include IL-1a, IL-1j3, TNF-a, IL-6, and IL-11 (Stashenko, 1994; 
Manolagas, 1995; Kawashima and Stashenko, 1999). It has also been 
demonstrated that when an infected root canal is thoroughly cleaned and 
debrided, rendering it free from bacteria and bacterial byproducts, pulpal and 
periapical inflammatory responses cease to occur and the damaged tissues heal 
themselves (Moller et aI, 1981). 
RNA interference (RNAi) is emerging as a new and potent method of gene 
silencing that selectively targets and shuts off the post-transcriptional expression 
of mRNA (Elbashir et al., 2001). In an effort to determine the implication of small 
interfering RNAs (siRNAs) for the inhibition of LPS-induced osteoclast formation 
and cytokine stimulation, the objective of this study was to suppress TLR4 or 
NFATc1 expression in monocytes and osteoclast cells using the RNAi technique. 
We hypothesized that knocking down the expression of TLR4 and NFATc1 in 
these cells with effective siRNA will modulate the effects of LPS stimulation. 
Thus, this study aimed to provide a potential therapeutic approach and open new 
horizons in the field of endodontic research. 
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Review of Literature 
Etiology of Apical Periodontitis 
Apical periodontitis is a local inflammatory destruction of the bone and 
periodontium around the apex of a tooth in response to an infection of endodontic 
origin (Moller et al. 2004). Although chemical and physical factors can also 
induce a peri radicular inflammatory response, evidence for the essential role of 
microbial agents in dental pulp infection and the pathogenesis of apical 
periodontitis is overwhelming and well-established (Kakehashi, 1965; Sundqvist, 
1976; Moller, 1981). 
The presence of bacteria in the necrotic dental pulp of teeth with 
associated pathologic conditions was reported more than a century ago, when 
Miller {1894} hypothesized that microorganisms are the causative agents of 
endodontic disease (Miller, 1894). However, it was not until a half century later, 
when the causal relationship between periapical inflammation and bacterial 
infection was convincingly demonstrated. In the classic study by Kakehashi et al. 
{1965}, it was shown that pulpal necrosis and periapical inflammation developed 
in rats subjected to mechanical pulp exposure and kept exposed to the 
conventional microbial environment of the oral cavity. Conversely, germ-free 
animals demonstrated minimal pulpal inflammation and no periapical destruction, 
and formed reparative dentin at the exposure sites, exhibiting the substantial 
healing capability of the pulp in the absence of infection (Kakehashi 1965). 
Subsequent animal and human studies confirmed the cause and effect 
relationship between pulpal infection and periapical pathology. 
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In his thesis, Sundqvist (1976) observed 32 traumatized incisors with 
pulpal necrosis, yet clinically intact crowns. Eighteen of the 19 (95%) teeth with 
associated periapical lesions presented with positive cultures for bacteria that 
were predominantly strict anaerobes, whereas no bacteria were cultivated from 
the 13 teeth without periapical lesions (Sundqvist, 1976). In a controlled monkey 
experiment in which the pulps of 26 teeth were rendered necrotic under sterile 
conditions and immediately sealed in the uninfected root canal, none developed 
apical periodontitis, even after 6-7 months of observation. In contrast, 47 of the 
52 (90%) teeth in which the pulps were deliberately infected prior to sealing of 
the access opening, exhibited periapical destruction (Moller et al., 1981). This 
study demonstrated that apical periodontitis can not be caused by necrotic pulp 
tissue per se, via toxic tissue breakdown products, but that the presence of 
bacteria within the pulp appears to be an absolute requirement for the 
development of periradicular disease. 
Studies on Endodontic Flora and Routes of Entry 
There are several pathways by which microorganisms may gain entry into 
the dental pulp. The most common may be through openings in the dental hard 
tissues as a result of the caries process, operative procedures, and trauma-
induced micro-cracks. Anachoresis, which is the transport of microorganisms via 
blood circulation to the area where they establish an infection, has also been 
proposed in cases where teeth with necrotic pulps and clinically intact crowns 
were observed (Robinson and Boling, 1941; Gier and Mitchel, 1968). However, 
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this theory remains controversial and the extent to which this may occur is 
unknown (Oelivanis and Fan, 1984). Another possible pathway for bacterial 
invasion and infection of the pulp may be through exposed dentinal tubules or 
accessory canals found at the cervical root surface in the periodontal pocket, 
although the importance of this pathway has also been debated (Seltzer et al., 
1963; Mazur and Massier, 1964). 
Over 500 bacterial species are currently recognized as normal inhabitants 
of the oral cavity and an additional 200 may still be detected by molecular 
methods (Moore and Moore, 1994; Munson et al., 2002). Although all have the 
theoretic capability and potential to invade and infect the pulp, induce periapical 
inflammation and bone destruction, only a small proportion of species have been 
consistently isolated from such root canals (Sundqvist, 1994). 
The necrotic root canal system provides a unique ecological niche for 
bacteria. The lack of oxygen supply, availability of host tissues, and inflammatory 
exudates produced at the bacteria-inflammatory tissue interface are the primary 
nutritional factors selecting for bacterial growth (Sundqvist, 1992). Studies have 
shown that the relative proportion of obligate anaerobes increases, and that of 
facultative bacteria decreases, with time elapsed after infection (Fabricius et al., 
1982; Tani-Ishii et ai, 1994). Bacteriologic sampling of necrotic root canals of 
chronically infected teeth with primary apical periodontitis indicate that the 
microbial population is predominantly anaerobic and Gram-negative 
(Bergenholtz, 1974; Sundqvist, 1976). Most of these species have also been 
identified in periodontal pockets (Moore, 1987; Socransky et al., 1988). The 
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anaerobic infection is usually polymicrobial, typically containing between 2 to 8 
species, with no more than 20 species having ever been found in one root canal 
(Dahlen and Haapasalo, 1998). Common species that have been isolated in 
both human and animal studies include Fusobacterium, Streptococcus, 
Prevotella, Eubacterium, Peptostreptococcus, Camphylobacter, Porphyromona, 
and Propionibacterium (Sundqvist, 1994). 
Bacterial interactions playa significant role in determining the composition 
and pathogenicity of the root canal flora. Virtually all microbes that are present in 
root canals have the potential to initiate a periapical reaction and bone 
destruction (Sundqvist, 1976). However, some combinations have a tendency to 
associate together, providing for a mutually supportive (synergistic) environment, 
whereas others may create negative (antagonistic) associations by competing for 
nutrients, thus inhibiting the growth of other bacteria (Greiner and Mayrand, 
1986; Sundqvist 1992). In studies conducted by Fabricius et al., bacteria 
originally isolated from the root canals of monkeys with periapically involved teeth 
were then inoculated in various combinations or as individual strains into the root 
canals of other monkeys. Infection of root canals with individual bacterial species 
produced a relatively mild periapical inflammation and little periapical destruction, 
whereas in combinations, the same bacterial species were highly pathogenic and 
capable of inducing more severe periapical reactions and larger areas of 
periapical destruction (Fabricius et a/., 1982b). These observations and later 
studies have confirmed that the virulence of individual species may vary 
considerably and highlight the importance of microbial synergy for the 
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pathogenicity of the endodontic flora (Dahlen et al., 1987). The pathogenic 
properties of these microorganisms are affected by a variety of factors which 
include: (1) the presence in sufficient numbers to initiate and maintain infection, 
(2) the ability to acquire nutrients from the host tissue for growth and survival, (3) 
the ability to evade, withstand, and/or alter host defenses, and (4) the synthesis 
and release of a variety of virulence factors including proteolytic enzymes, 
metabolites, and cell wall components-such as endotoxin (lipopolysaccharide, 
LPS) from Gram-negative bacteria and proteoglycans from Gram-positive 
bacteria--into the periapical area where they are capable of damaging host 
tissues (Horiba et al., 1991; Hashioka et al., 1994). LPS, in particular, is the best 
studied of these virulence factors, and has also been identified as a highly potent 
initiator of inflammation and a major factor in bone resorption (Dwyer and 
Torabinejad, 1981; Dahlen et al., 1981; Schonfeld et al., 1982). 
Bacterial Endotoxin-Lipopolysaccharide (LPS) 
Structure 
Bacterial lipopolysaccharide (LPS) is a fundamental component of the cell 
wall of Gram-negative organisms (Figure 1). One bacterial cell contains 
approximately 106 LPS molecules, occupying roughly 75% of its outer membrane 
(Nikaido, 1996). Although there is a great compositional variation among 
lipopolysaccharides derived from different groups of Gram-negative bacteria, 
they all have a common basic structure. They are complex glycolipids, consisting 
of a hydrophilic heteropolysaccharide and a covalently bound hydrophobic lipid 
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domain known as lipid A (Luderitz et a/. , 1982). The heteropolysaccharide part 
can be divided into two subdomains, the O-specific polysaccharide chain and the 
core glycolipid (Figure 2). Lipid A serves as the base structure which secures the 
LPS molecule within the bacterial membrane, while the polysaccharide 
component interacts with the external environment. 
LPS 
o antlgflfl 
... - repeat 
Glucose Ouler Hepto } 
G.I .. ~tO$e core 
Heptose } nnor 
Kdo eo,.. 
I lipid A I 
Ptotein 
Figure 1. General structure of a Gram-negative bacterial cell wall. The inner and outer 
membrane are separated by a periplasmic space which contains peptidoglycan. 
Lipopolysaccharide (LPS) is found in the outer membrane and consists of three parts: Lipid A, 
core glycolipid, and O-specific chain. Kdo forms a covalent bond between the core and lipid A. 
Image modified from: edoc.hu-berlin.deI.../HTMLlchapter1.html 
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Gram-negative bacterial endotoxin (lipopolysaccharide, LPS) 
Core glycolipid 
O-specific polysaccharide chain 
O-specific 
oligosaccharide 
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Figure 2. General chemical structure of lipopolysaccharide showing the O-specific chain, core 
glycolipid (composed of inner and outer regions), and lipid A. Image obtained from: 
frees pace. virg in.netlr .barclay/edtxsch1.htm 
O-specific Chain (O-antigen) 
The O-specific chain is a complex polysaccharide composed of one to 
eight repeating units of identical glycosyl residues. There are enormous structural 
diversities in O-chains. The length, linkages, and fine structure of the O-chain 
structure vary from strain to strain, functioning as an important surface antigen, 
and thus define the serotype specificity of LPS and each bacterial strain 
containing them (Rietschel et al., 1991). The O-antigen possesses several 
intrinsic biological activities and although it's not required for growth in-vitro, its 
presence is known to help bacteria evade the host immune system and other 
environmental disturbances (Rietschel et al., 1992). However, not all Gram-
negative bacteria possess an O-specifc chain. Such mutants produce rigid, 
rough-looking colonies when grown on solid agar and are accordingly termed 
"rough" (R), whereas wild-type bacterial species containing the O-antigen form 
colonies with a smooth morphological appearance and are termed "smooth" (S). 
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Core Region 
The core region of LPS can be subdivided into an outer and inner region 
(Figure 1). Although it is structurally more uniform than the O-chain, some 
structural variances are found, mainly in the outer core. The outer core region 
usually consists of common hexose residues such as D-glucose, D-galactose, 
and N-acetyl-D-glucosarnine. The proximal inner part of the core region is 
composed of specific a heptose residue, primarily in the L-glycero-D-manno 
configuration, and 3-deoxy-D-manno-oct-2-ulopyranosonic acid (Kdo) (Holst and 
Brade, 1992). Although core regions may vary among bacterial species, the 
inner core region containing Kdo appears to be well conserved among all Gram-
negative bacteria, as Kdo forms the linkage by which the core is covalently 
bound to lipid A (Caroff et a/., 2002). It has long been believed that the minimal 
LPS structure required for viability of Gram-negative organisms consists of lipid A 
linked to only two Kdo residues (Raetz, 1990; Schnaitman and Klena, 1993), 
however viable mutants lacking Kdo and with the basic tetra-acyl form of lipid A, 
termed lipid IVa, have recently been experimentally produced. These results 
suggest that lipid IVa may indeed be the actual minimal LPS structural 
requirement (Meredith et a/' J 2006). It is unclear what, if any biologic activities 
the outer core region of LPS is responsible for, however, it is thought that both 
the inner and outer core contain epitopes that are recognized by host antibodies 
(Rietschel et a/' J 1992). 
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Lipid A 
Lipid A is a unique and distinctive glucosamine-based phospholipid that 
anchors LPS to the outer membrane of the gram-negative bacterial cell wall 
(Raetz, 1990). It is generally composed of a phosphorylated ~ 1 ,6-linked 0-
glucosamine disaccharide that carries up to six or seven fatty acid chains 
(Zahringer et., al 1999). It, along with the Kdo-containil1g inner core region, 
represents the most structurally conserved region among all Gram-negative 
species (Figure 3). However, variations can occur in the fine structure, arising 
from differences in the length, position, and number of the acyl groups. 
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Kdo;a,lipid A 
(Re Endotoxin) 
14 14 14 
Figure 3. Structure of Kdo(2)-lipid A found in E.coli, similar to that found in most pathogenic 
Gram-negative bacteria. Image from: www.lipidlibrary.co.uklLipidsllipidAiindex.htm 
It has been demonstrated that lipid A is the region of LPS that is 
responsible for many of the pathologic effects associated with Gram-negative 
bacterial infection, since free lipid A has been shown to reproduce the toxic 
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effects of LPS (Galanos et al., 1985). Additional studies have confirmed the role 
of lipid A by using chemically synthesized homologues and partial structures that 
were able to produce identical effects (Kusumoto et al., 1984; Imoto et al., 1987). 
This structure, called compound 506, was shown to be identical to E. coli lipid A 
purified in a variety of biological assays, and was able to optimally express a full 
spectrum of endotoxic activities (Galanos et al., 1985; Kotani 1985). Based on 
these findings it was concluded that the cytokine inducing capacity of compound 
506 was solely attributed to its three dimensional structure, and that the natural 
form of this compound represents the optimal configuration for 
immunostimulatory effects. 
Host Response 
When describing the effects of LPS on the host's tissues, perhaps the 
author Lewis Thomas stated it best in The lives of a Cell: "This oppressive 
uncontrolled and autodestructive behavior of the host is what makes endotoxin a 
venom ...... they are read by our tissues as the worst of news .... when we sense 
LPS, we will use all the defenses at our disposal to bomb, block, seal off, and 
destroy all tissues in the area" (Thomas, 1974). Since that time, much has been 
studied about the structure and basic principles of LPS bioactivity and its 
mechanism of action are now well understood (Raetz et al., 1991; Galanos and 
Freudenberg, 1993). When Gram-negative bacteria die or multiply, LPS is 
liberated and released into the host tissue where it can initiate an inflammatory 
response (Rietschel and Brade, 1992a; Barthel et al., 1997) and ultimately result 
in periapical bone destruction (Stashenko, 1990; Yamasaki et al., 1992). It has 
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been thought that most, if not all, of the pathogenic effects of LPS are not direct, 
but rather induced indirectly through its interaction with various host cells. LPS 
stimulates monocytes, macrophages, and various other host cells to produce and 
release a large number of pro-inflammatory cytokines such as tumor necrosis 
factor-a (TNF-a), interleukin (IL)-1, IL-6, IL-8, IL-11, and IL-12 as well as a variety 
of other small molecules such as lipid mediators, oxygen radicals, and enzymes 
(Raetz, 1990; Cohen, 2002). These mediators can then exert either a local or 
systemic response by acting independently, sequentially, synergistically or 
antagonistically to induce many of the typical effects of LPS (Rietschel and 
Brade, 1992a). In addition to its proinflammatory effects, LPS has been shown to 
be a potent stimulator of bone resorption by acting on the production and release 
of cytokines that influence osteoclast differentiation and activation (Ito et al., 
1996; Kikuchi et al., 2001; Jiang et al., 2003). Particularly, LPS has been 
experimentally shown to stimulate tissue destruction and alveolar bone 
resorption in vitro using a mouse osteoblast tissue culture (Pelt et al., 2002) and 
also in vivo using a rat model (Umezu et al., 1989). 
Implication in Endodontic Infections 
Numerous studies have reported the presence of LPS in samples taken 
from the root canals of necrotic teeth (Schein and Schilder, 1975; Schonfeld et 
al., 1982) and the pulpal-dentinal wall of teeth with apical periodontitis (Horiba et 
al., 1990). Other studies have confirmed a strong correlation between the levels 
of LPS and Gram-negative bacteria found in the infected root canal (Dahlen and 
Bergenholtz, 1980). Using a rat model, it was shown that LPS released as a 
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result of death or multiplication of bacteria within the root canal can pass through 
the apical foramen and into the periapical tissues where they increase in levels 
from 1 to 70 days after pulp exposure (Yamasaki et al., 1992). The introduction 
of LPS from F. nucleatum into sterile root canals of teeth in monkeys was shown 
to induce periapical inflammation and bone resorption (Dahlen et al., 1981). 
Similarly, the direct application of S. Minnesota, E. corrodens, and E. coli LPS to 
the dental pulp also induced significant bone destruction in dogs (Pitts et al., 
1982; Mattison et al., 1987). 
Associations have also been found between the LPS content of infected 
teeth with pulp necroses and clinical endodontic symptoms such as spontaneous 
pain, tenderness to percussion, and exudation (Horiba et aL, 1991). LPS can 
contribute to the release of increased levels of vasoactive and neurotransmitter 
chemicals close to nerve endings in the periapical tissues, resulting in pain 
(Seltzer and Farber, 1994). 
Calcium hydroxide has been shown to inactivate LPS in in vitro studies by 
hydrolyzing the highly toxic lipid A component into fatty acids and amino sugars 
which are non-toxic molecules (Safavi and Nichols 1993, 1994; Barthel et al., 
1997; Olsen et al., 1999). Silva et al. (2002) carried out a study in dogs in which 
they showed that LPS did not induce the formation of periapical lesions in teeth 
when combined with calcium hydroxide, confirming the detoxifying role of calcium 
hydroxide in vivo. The above findings, as a whole, strongly support the 
connection between LPS and the significant role they play in the pathogenesis of 
apical periodontitis. 
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Host Recognition of LPS 
The molecular mechanism by which host cells recognize bacterial 
components has been extensively studied and vast breakthroughs have been 
made in the identification of molecules in the "LPS receptor complex" , which play 
a crucial role in recognizing, binding, and mediating the LPS response. The 
specific mechanism involved in recognition of LPS by host cells were first 
identified in 1990 (Schumann et a/., 1990; Wright et a/., 1990). The basic 
mechanism is that LPS is first recognized by, and then forms a complex with, the 
soluble LPS-binding protein (LBP). LBP is a lipid transfer molecule that 
catalyzes the movement of phospholipids. These LPS/LPB complexes are then 
transferred to the membrane bound CD14 receptor, causing a conformational 
change, that allows LPS to be transferred to the Toll-like receptor 4 (TLR4) and 
myeloid differentiation protein-2 (MD-2) (Hailman et aI., 1994; Tobias et a/., 
1995) (Figure 4). These three proteins-CD14, TLR4, and MO-2 are referred to 
LRR 
TLR4 LPS ) 4 LBP 
CDI4 
Cytoplas 
Adaplor 
proteins 
as the "LPS receptor complex". 
Figure 4. Schematic diagram of the LPS 
receptor complex. LPS is recognized by a 
complex of three proteins: CD14, TLR4, and 
MD-2. LPS is first bound by LBP which then 
transfers it to CD 14. CD 14 then presents LPS to 
TLR4-MD-2. TLR4 is the actual LPS receptor. It 
is a transmembrane protein characterized by an 
extracellular domain containing multiple leucine-
rich repeats (LRR) , a transmembrane domain, 
and an intracellular TlR domain. TLR4 mediates 
an intracellular signal transduction through three 
adaptor proteins including MyD88, TlRAP, and 
TRIF. Image obtained from Fujihara et aI, 2003. 
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The LPS receptor com plex 
CD14 
CD14 is a 55-kDa glycoprotein that can be found in two forms. The first is 
a soluble CD14 (sCD14) which can be found in plasma, where they are able to 
interact directly with the LPS/LPB complex and enable the activation of LPS 
signaling in cells that lack the membrane-bound CD14, e.g. endothelial cells, 
fibroblasts, and smooth muscle cells to induce cytokine production (Pugin et al., 
1993; Tapping and Tobias, 1997). The second and more extensively studied 
form is the membrane CD14 (mCD14), which is embedded in the plasma 
membrane of myeloid cells via a glycosylphosphatidynositol linkage (Haziot et 
al., 1988; Wright et al., 1990). It is composed of 10 copies of a leucine-rich 
repeat (LRR) domain. LRRs are commonly found in various proteins that are 
involved in substrate recognition and signal transduction (Bell et al., 2003). The 
binding of LPS to mCD14 on monocytes and macrophages is essential for their 
activation and can significantly reduce the concentration of LPS required for the 
stimulation of these cells as compared with LPS alone by 100 to 1000-fold. 
Antibodies to CD14 have been shown to significantly inhibit the binding of 
LPS/LBP and reduce cytokine production of myeloid cells in response to LPS 
(Wright et al., 1990). Additional studies have shown that CD14-knock-out (CD14-
1-) mice are more resistant to LPS-induced lethal shock and produced 
significantly decreased levels of cytokines when stimulated with LPS (Haziot et 
al., 1996; Moore et al., 2000). Thus, CD14 was originally identified as a specific 
receptor for LPS, even though the dependency on CD14 could be partially 
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overcome with higher concentrations of LPS (Perera et al., 2001). However, 
since CD14 lacks transmembrane and intracellular domains (Figure 4), it cannot 
by itself initiate a signal transduction in response to LPS, and additional 
membrane molecules seemed to be necessary for cellular activation. Several 
biochemical and genetic studies support the theory that CD14 binds LPS, but 
does not participate directly in signaling (Wright, 1999). Subsequent studies have 
since shown that TLR4 is the actual signal-transducing receptor for LPS 
(Poltorak et aI., 1998). It now appears that the role played by CD14 in LPS 
signaling is to bind LPS and present it to TLR4 and MD-2. Furthermore, CD14 
has been shown to participate in recognition of various bacterial components 
other than LPS, including Gram-positive cell-wall components such as 
peptidoglycan (Pug in et al., 1994). CD14 appears able to differentiate between 
bacterial products and to present them to various TLRs (Muroi et al., 2002). 
TLR4 
The presence of pattern recognition receptors on immune cells, with the 
ability to detect and dispose of infectious microbial pathogens without interfering 
with its own host tissues was put forth to describe the basic concept of innate 
immunity (Janeway, 1992; Hoffmann et al., 1999). These receptors recognize 
bacterial products that often share a common molecular pattern and are highly 
conserved among microorganisms, called the pathogen associated molecular 
pattern (PAMP), such as LPS in the case of Gram-negative bacteria (Janeway, 
1989). It was only in 1996, when a study in Drosophila, which only possess an 
innate immune system, led to the discovery of the Toll as an essential receptor 
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for host defense against fungal infection (Lemaitre et a/., 1996). To date, at least 
10 homologues of Toll, referred to as Toll-like receptors (TLRs) (TLR1-TLR10), 
have been identified in mammalian species, and 7 of them (TLR 1, TLR 2, TLR3, 
TLR4, TLR5, TLR6, and TLR9) have been shown to be required for the 
recognition and signaling of specific microbial components derived from 
pathogens including bacteria fungi, protozoa, and viruses (Poltorak et a/., 1998; 
Schwandner et a/., 1999; Yoshimura et a/., 1999; Hemmi et a/., 2000; Wyllie et 
aI., 2000; Alexopoulou et a/., 2001; Hayashi et a/., 2001; Takeuchi et a/., 2001). 
The structural hallmark of all known Toll proteins, which represent type I 
receptors are an extracellular domain containing multiple LRRs, a single 
transmembrane region, and an intracellular region known as the "TIR" domain 
which is homologous to the Drosophila Toll and the mammalian IL-1 receptor 
(Gay and Keith, 1991) (Figure 4). The distinct responses to specific microbial 
products are a result of minor variances in the extra- and intracellular domains of 
TLRs. 
The first human TLR to be identified was TLR4, and is predominantly 
found on immune cells such as macrophages and dendritic cells. There is now 
compelling evidence that TLR4 is in fact an essential signal-transducing receptor 
for LPS (Medzhitov et a/., 1997). The establishment of a link between TLR4 and 
LPS recognition came through the use of positional cloning studies of the Lps 
locus in C3H/HeJ and C57BLl10ScCr mice which are both insensitive to LPS. 
The Lps locus contains the Tlr4 gene and both of these mice were shown to have 
mutations in this region. C3H/HeJ mice were shown to have a single point 
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mutation in the TIR domain of Tlr4 which causes proline to be replaced with 
histidine at position 712 of the polypeptide chain, whereas C57BLl10ScCr mice 
were shown to have a null mutation, resulting in total deletion of the Tlr4 gene 
(Poltorak et al., 1998; Qureshi et al., 1999). The essential role of TLR4 for LPS 
signaling was further confirmed when mice rendered deficient in the Tlr4 gene 
(TLR4 knockout mice) where shown to be as insensitive to LPS as C3H/HeJ 
mice (Hoshino et al., 1999). TLR4 mutations are also associated with a 
decreased response to LPS in humans (Arbour et al., 2000). Conversely, 
transfection of TLR4 in human embryonic kidney cells that were unresponsive to 
LPS was shown to restore the LPS response (Chow et al., 1999). 
TLR4, however, is not only exclusively involved in enterobacterial LPS 
signal transduction. It is also implicated in the recognition of several other 
endogenous and exogenous ligands. These include heat-sensitive cell-
associated factor derived from Mycobacterium tuberculosis (Means et al., 1999), 
Taxol, which is a diterpene purified from the bark of the Western yew (Taxus 
brevifolt) (Kawasaki et al., 2000), heat shock protein 60 (Vabulas et al., 2001), 
fusion (F) protein of respiratory syncytial virus (Kurt-Jones et al., 2000), as well 
as oligosaccharides of hyaluronic acid, heparin sulfate, and fibrinogen (Takeda et 
al., 2003). 
Ambiguous Role of TLR2 
There is a general consensus that TLR2 is involved in the recognition of 
components from a variety of microorganisms. These include Gram-positive, 
mycobacterial, and fungal compounds such as peptidoglycan, lipoteichoic acid, 
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various lipopeptides, and lipoarabinomannan (Lien et a/., 1999). However, TLR2 
was also originally believed to be the long sought after LPS receptor. This was 
based on several transfection studies that showed that expression of the 
mammalian TLR2 in human embryonic kidney cells that were LPS-unresponsive 
were now capable of responding to LPS (Kirschning et a/., 1998; Yang et aI., 
1998). However, later studies revealed that overexpression of TLR2 causes cell 
lines to become exceedingly sensitive to trace amounts of non-LPS lipopeptide 
contaminants that may have been present in the LPS preparations (Heine et a/., 
1999; Takeuchi et a/., 1999; Faure et a/., 2000). Repurification of LPS 
preparations of Sa/monella and E. coli clearly demonstrated that cells are 
activated through TLR4 as the principal signal-transducing molecule, and not 
TLR2 (Hirschfeld et a/., 2000; Tapping et a/., 2000). Furthermore, similar types 
of LPS elicited the same response in TLR2 knockout mice as in wild-type mice 
(Takeuchi et a/., 1999). 
Adding to the complexity of LPS signaling, it now appears that the 
chemical structure of LPS itself may be an important factor in its recognition by 
different receptor clusters, resulting in different cellular responses (Hirschfeld et 
a/., 2001; Werts et a/., 2001). Historically, most of the reported studies have 
been performed using commercially available preparations of LPS of E. coli or 
Sa/monella. However, recent publications indicate that not all LPS chemotypes 
induce signal transduction through TLR4, specifically LPS of Leptospira 
in terrogans, Porphyromonas gingiva/is, and Neisseria meningitidis have been 
shown to signal via TLR2 (Werts et a/., 2001; Bainbridge and Darveau, 2001; 
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Pridmore et al., 2001). A recent study suggests that the lipid A segment of these 
bacterial species may exhibit several chemical modifications, specifically in the 
number of acyl chains, which alters the shape of the LPS molecule, 
distinguishing them from the typical LPS of Gram-negative bacteria (Netea et al., 
2002). Thus, TLR2 may recognize distinct epitopes within lipid A of L. 
interrogans, P. gingivalis, and N. Meningitidis, in addition to other structurally 
unrelated components from Gram-positive bacteria. 
Although TLRs are believed to be the main receptors involved in LPS 
signal transduction, new experiments have identified an additional heterogenous 
complex of four proteins that may be involved in LPS recognition and signal 
activation. Using antibodies against Hsp70, Hsp90, CXCR4, and GOF-5, 
researchers were able to inhibit LPS-induced TNF-a production and activation of 
monocytes (Triantafilou et al. 2001; Triantafilou et a/. 2001 a). Thus, it appears 
probable that there are a host of several membrane proteins that form an LPS 
receptor domain. 
MD-2 
1\110-2 is a small secreted glycoprotein that lacks a transmembrane 
domain, which acts as an extracellular adaptor protein in conjunction with TLR4, 
and is essential for LPS signaling to occur (Shimazu et al., 1999) (Figure 4). The 
physiologic necessity for MO-2 in the LPS response has been demonstrated 
using a mutant form of mice which lack MO-2 (Nagai et al., 2002). Bone marrow-
derived macrophages from mice lacking MO-2 were unable to produce 
inflammatory cytokines upon stimulation by LPS. These findings were reinforced 
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in a study using a mutant cell line derived from Chinese hamster fibroblasts in 
which there was normal cell surface expression of TLR4, but also a point 
mutation in a conserved region of MD-2 (C95Y) that showed no response to LPS. 
Additionally, in another study, wild-type MD-2 was able to restore the LPS 
response in cells expressing TLR4 but lacking MD-2 (Schromm et al., 2001; 
Visintin et al., 2001). 
It has also been demonstrated that MD-2 is involved in regulating the 
intracellular positioning of TLR4 (Nagai et aI., 2002). In embryonic fibroblasts 
lacking MD-2, TLR4 predominantly accumulated within the Golgi apparatus and 
failed to be correctly transported to the cell surface. 
Thus it appears that MD-2 plays a pivotal role, having both a regulatory 
activity for the cellular distribution of TLR4, and also involved in LPS recognition 
and signal transduction through TLR4. In fact, LPS binds to MD-2, which then 
associates with TLR4 by means of the extracellular LRRs, inducing NF-KB 
activation and signaling via TLR4 (Visintin et al., 2003). It therefore seems 
plausible that the functional integrity of the "LPS Receptor Complex" depends on 
the cell surface expression of a variety of host proteins and the concept of a 
"monogamous" relationship between LPS and TLR4 may in reality be an 
oversimplification. 
LPS Signaling through TLR4 
My088-0ependent Signaling Pathway 
Since the TLRs share sequence homology with the IL-1 receptor family, 
LPS sjgnaling is thought to occur in a similar manner. These two pathways, are 
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in fact, mediated by common components. The principle signaling pathway 
activated by TLR4 in response to LPS occurs through sequential recruitment of 
adapter proteins. These adapters include myeloid differentiation factor 88 
(MyD88), a family of IL-1 receptor-associated kinases (IRAK), and TNF receptor-
activated factor 6 (TRAF6) (Muzio et al., 1996; Burns et al., 1998; Medzhitov et 
al., 1998). The cytoplasmic adapter MyD88, which is also a Toll-like molecule, is 
normally bound to the intracellular "TIR" domain of TLR4 by TolllToll interactions. 
Upon stimulation, MyD88 recruits IRAK-4 to the receptor complex which then 
facilitates the phosphorylation of IRAK-1. Activated IRAK-1 subsequently 
dissociates from the receptor complex and interacts with TRAF6, which results in 
the activation of two distinct signaling pathways, NF-KB or c-jun N-terminal 
kinase (JNK), both of which are involved in the activation of numerous 
inflammatory genes and expression of inflammatory cytokines (Figure 5) (Cao et 
al. , 1996; Muzio et al., 1997; Burns et aI., 1998; Medzhitov et al., 1998. Muzio et 
al.,1998). Additionally, gene targeting studies have shown that NF-KB has a 
critical role in osteoclast differentiation (Franzoso et aI., 1997; lotsova et aI., 
1997). 
Figure 5. Schematic diagram of the My088-
dependent and My088-independent pathways. 
Refer to text for explanations. 
Image obtained from: 
www.rsc.org/delivery/ ArticleLinking/Display 
H ... 
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My088-lndependent Signaling Pathway 
Although MyD88 is an absolute requirement for the production of 
inflammatory cytokines, MyD88-deficient macrophages showed a delayed 
activation of the NF-KB and JNK pathways in response to LPS stimulation 
compared with macrophages from wild-type mice (Kawai et al., 1999). This 
indicates that even though LPS-induced inflammatory cytokine production is 
entirely dependent on the MyD88 pathway, there also exists a MyD88-
independent component in LPS-TLR4 signaling. 
LPS stimulation of MyD88-deficient macrophages leads to activation of the 
transcription factor IFN-regulatory factor 3 (IRF-3), which subsequently induces 
IFN-~. IFN-~ then activates Stat1, which results in the expression of several IFN-
inducible genes (Figure 5) (Kawai et al., 2001; Doyle et al., 2002; Toshchakov et 
al., 2002). 
Regulation of Osteoclast Formation 
Osteoclasts are large, multinucleated specialized giant cells responsible 
for bone resorption that arise from a hematopoietic stem cell lineage of 
monocytes and macrophages (Suda et al., 1992). Osteoclastic bone resorption 
consists of multiple steps and studies have identified several key elements 
thought to be important for osteoclast differentiation (osteoclastogenesis) and 
activation (Teitelbaum and Ross, 2003). These include macrophage-colony 
stimulating factor (M-CSF), receptor activator of nuclear factor kappa B ligand 
(RANKL), tumor necrosis factor-a (TNF-a), interferons (IFNs), and interleukins 
(I Ls). Of these factors, M-CSF and RANKL are thought to play an essential role 
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The in vivo significance of the RANKL-RANK signaling pathway in 
regulating skeletal development and bone remodeling has been demonstrated by 
a series of gene disruption studies using a mouse model (Teitelbaum and Ross, 
2003). Mice lacking either RANKL or RANK developed severe osteopetrosis, 
with total occlusion of the bone marrow space within endosteal bone, due to 
failure to form osteoclasts (Dougall et al .. 1999; Kong et al., 1999). Conversely, 
the targeted disruption of OPG led to the development of early onset 
osteoporosis due to increased numbers of activated osteoclasts (Bucay et al., 
1998). 
RANK Signaling in Osteoclast Differentiation 
RANK signaling is mediated through specific adapter molecules called 
TNFR-associated factors (TRAFs) (Rho et al., 2004). Although the TRAF family 
contains six members (TRAFs 1, 2, 3, 4. 5. and 6), and RANK can directly 
interact with five of them (TRAFs 1. 2, 3, 5, and 6), only TRAF-6 appears to be 
critical for osteoclast differentiation (Galibert et al., 1998; Darnay et a/., 1999). 
RANKL stimulation facilitates the recruitment of TRAF6 to one or more of the 
three binding motifs in the cytoplasmic domain of the RANK receptor which then 
activates several downstream signaling cascades. Six key signaling pathways 
have been identified in osteoclasts: nuclear factor of activated T-cell (NFAT) c1. 
nuclear factor kappa B (NF-kB), Aktlprotein kinase B (PKB). Jun N-terminal 
kinase (JNK), extracellular signal-regulated kinase (ERK) and p38. all of which 
promote survival and differentiation (Figure 7) (Boyle et a/., 2003). 
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Figure 7. Schematic representation of RANK signaling in osteoclast differentiation. Modified 
from Feng, 2005. 
However, recent findings support the notion that LPS and some 
inflammatory cytokines such as TNF-a and IL-1 may also be directly involved in 
osteoclast differentiation and activation through a mechanism partially 
independent from that of the RANKL-RANK interaction (Jimi et ai, 1999; Suda et 
al., 2002; Kobayashi et al., 2000; Jiang et al., 2006). The intracellular signaling 
cascade of TLR4 is similar to that of IL-1 receptors and both of these receptors 
have been shown to use TRAF6 as a common signaling adapter molecule 
(Kobayashi et al., 2004). When osteoclast precursors were stimulated with both 
LPS and RANKL, LPS-induced osteoclast formation was observed even in the 
presence of OPG and IL-1 receptor antagonists (Suda et al., 2002; Jiang et al., 
2006). Osteoclast formation was also stimulated by LPS in preosteoclast cells 
from mice missing tumor necrosis factor (TNF)-receptor-I or TNF-receptor-II 
(Suda et al., 2002). These results suggest that LPS stimulates osteoclast 
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formation independent of RANKL, IL-1, or TNF-alpha action, and have opened 
new areas for exploring the molecular mechanisms of osteoclast differentiation. 
They also constitute a potential therapeutic target for the modulation of excessive 
osteoclast differentiation in pathogenic bone and oral diseases (Figure 8). 
TNF-a RANKL IL-1 LPS 
/\ l 
TLR4 
I NF-KB, JNK, NFATc1, etc. I 
r;\ _~ __ ~. ~ ••• ~NF"'B' JNK, ~FAT'" .':- I@.: ••• 
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precursor M-CSF Osteoclast 
Figure 8. Schematic representation of osteoclast activation by RANKL, IL-l, and LPS through 
their respective receptors. TRAF6 appears to act as a common signaling adapter molecule 
involved in all three pathways. Modified from Katagiri and Takahashi 2002. 
NFATc1 
NFATc1 is the most strongly induced transcription factor gene mediated 
by RANKL stimulation. It has also been shown to be a key regulator of 
osteoclastogenesis and plays a critical role in the terminal differentiation of 
osteoclasts (Takayanagi et al., 2002). RANKL-induced recruitment of TRAF6 
results in the induction of intracellular calcium, which leads to the activation of 
calcineurin (Takayanagi et al., 2002). Activated calcineurin then 
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dephosphorylates and activates NFAT1, allowing it to translocate to the nucleus 
to form a ternary complex with c-Fos and c-Jun to stimulate NFATc1 gene 
expression (Figure 7) (Ikeda et al., 2004). At the final stage of osteoclast 
differentiation, NFATc1 works in conjunction with Fos and Jun proteins to 
stimulate osteoclast-specific genes such as tartrate-resistant acid phosphatase 
(TRAP), calcitonin receptor, and cathepsin K (Ikeda et al., 2004). Thus it 
appears that the NFATc1 pathway is a crucial component of osteoclast 
differentiation, and inhibition of this pathway may provide yet another potential 
therapeutic approach for the treatment of bone diseases. 
RNA Interference (RNAi) 
RNA interference (RNAi) is a process in which specific sequences of small 
pieces of double-stranded RNA (small interfering RNA [siRNA]) are used to 
silence the expression level of sequence-homologous genes (Dykxhoorn and 
Lieberman, 2005). It now appears that it is an evolutionary conserved process in 
plants and invertebrates that may have originated as a cellular defense, whose 
natural function is to protect cells against viral infection and other potentially 
harmful genetic elements that make double-stranded RNA (dsRNA) 
intermediates (Lee and Ambros, 2001). 
RNAi is arguably one of the most significant and promising technological 
advances in modern scientific history. Science magazine hailed it as the 
"Breakthrough of the Year" in 2002, and in 2006 the Nobel Prize in Physiology or 
Medicine was awarded to those responsible for its discovery. This phenomenon 
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was first discovered in plants when researchers were trying to genetically 
engineer a more intensely colored petunia using a transcribed sense transgene 
that encoded an enzyme for the synthesis of purple pigment, but unexpectedly 
found suppression of the homologous endogenous gene (Napoli et al., 1990). 
This was termed post-transcriptional gene silencing (PTGS). However, it was 
Andrew Fire, Craig Mello, and colleagues who made the discovery that 
sequence-specific dsRNA was the source of gene silencing in the nematode 
worm-Caenorhabditis elegans-and termed this RNA interference (Fire et al., 
1998). In their experiment, they separately introduced sense and antisense RNA 
to a particular gene into the cells of the worm and found, at best, the antisense 
RNA caused a modest reduction in gene expression. Yet, when both molecules 
were allowed to hybridize and then injected, there was a profound and specific 
interference. 
Additional studies revealed that when long dsRNA molecules are 
introduced in plants and invertebrates, they are internally processed by an 
enzyme called Dicer into small dsRNAs, 21 to 23 nucleotides (nt) in length, 
referred to as siRNA (Hammond et al., 2000, Zamore et al., 2000; Bernstein et 
al., 2001). However, in mammals, exposure to dsRNAs greater than 30 base 
pairs provokes a systemic and nonspecific inhibition of mRNA translation as a 
result of activation of the antiviral interferon response (McManus and Sharp, 
2002). It was thus a significant breakthrough when, in 2001, it was demonstrated 
that chemically synthesized short dsRNA molecules of 21-22 nt in length-
siRNA-could be used to directly trigger RNAi in mammalian cells without 
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initiating the interferon response (Elbashir et al., 2001). Since then, RNAi has 
revolutionized biological research as a new and powerful tool for the study gene 
function by suppressing its expression, and attracted the attention of academic 
researchers, the medical community, and the pharmaceutical industry for its 
potential therapeutic applications in the treatment of disease. 
Mechanism of RNA Interference 
RNAi is triggered when the host cell encounters long dsRNAs produced by 
viral sources or exogenously administered synthetic siRNA precursors (Lee and 
Ambros, 2001). Once in the cytoplasm, these RNA molecules are processed by 
the ribonuclease III-like enzyme known as Dicer, to generate RNA duplexes 21-
22 nt in length (siRNA) with a 2- to 3-nucleotide unpaired overhang at each end 
(Elbashir et al., 2001 a). These siRNA fragments are then incorporated into large 
protein complex, known as the RNA-induced silencing complex (RiSe), by which 
the double-stranded siRNA is unwound into single-stranded siRNA (Nykanen et 
al., 2001). The antisense strand of the duplex siRNA then guides the RiSe 
complex to the homologous mRNA. Once bound to its target through simple 
Watson and erick base paring, RiSe is activated by ATP and cleaves the mRNA 
at a single site approximately in the middle of the region paired with the 
antisense siRNA, resulting in silencing of the target gene (Elbashir et al., 2001a; 
Martinez et al' J 2002). The cleavage products are degraded and released from 
the siRNA-RiSe complex, freeing it to search for and further diminish the 
available pool of target mRNA (Figure 9) (Meister and Tuschl, 2004). 
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Figure 9. Schematic representation of the RNAi mechanism. RNAi is induced when the host cell 
encounters long dsRNA from viruses or exogenously administered synthetic siRNA. Once in the 
cytoplasm, they undergo processing by an enzyme called Dicer. This results in the formation of a 
dsRNA between 21-23 nucleotides in length. This siRNA binds with several cellular proteins 
forming a complex referred to as RNA interfering silencing complex (RISe), which guides the 
siRNA to its homologous target mRNA. Once bound to its target through simple Watson and 
erick base paring, RISe then cleaves the mRNA approximately in the middle of the region paired 
with the antisense siRNA, and effectively leads to further degradation of the mRNA. 
Image obtained from: http://arunbt.googlepages.com/ 
Design of Effective siRNA probes 
Functional RNAi is dependent upon the sequence specificity of the siRNA 
probe to the target gene of interest. Thus, design of the siRNA sequence is 
crucial for effective gene silencing. Currently, siRNA design is based on an 
understanding of RNAi biochemistry, and several groups have developed 
empirical guidelines for effective siRNAs design. These guidelines recommend 
33 
the use of siRNAs that are 21 nt long with a 3' overhang of 2 nucleotides. The 
siRNA should be complimentary to the target mRNA at a location 75-100 bases 
downstream of the start codon of the gene of interest and the target site should 
have a GC content less than 50 percent. Finally, a BLAST-search of the target 
site should be carried out to the appropriate genome database to ensure that 
only one gene is being targeted and 3-4 siRNA should be tested for each gene to 
minimize possible nonspecific off-target effects (Elbashir et al. 2001 b, Khvorova 
et al., 2003; Reynolds et al., 2004). At this time, the siRNAs of many gene 
products of interest have been synthesized and act as readymade Dicer 
products. 
Delivery Strategies of siRNA 
The delivery of nucleic acids into mammalian cells is called transfection. 
Functional RNAi requires effective transfection procedures without side-effects or 
cytotoxicity. Successful introduction of siRNA into cells of interest have been 
demonstrated using either plasmid or viral vectors (Brummelkamp et al., 2002; 
Paddison et al., 2002). Synthetic siRNAs delivered to cells in culture by 
electroporation or the use of lipophilic agents have also been used to 
successfully silence target gene expression (Elbashir et al., 2002; Mellitzer et al., 
2002). There are several commercially available transfection kits that can be 
used for the application of RNAi. Lipofectamine 2000 and Oligofectamine 
(Invitrogen) are two that are routinely used for siRNA delivery. 
34 
Therapeutic Potential of RNAi 
Given that most diseases are genetic-based and the genetic etiology of 
many disorders has been defined, the therapeutic promises of RNAi are 
potentially enormous. It seems evident that RNAi is not only a powerful research 
tool for studying gene function, but that it is also a fast and inexpensive method 
to selectively silence a gene product in complex biological systems. The 
sequence-specific gene inhibition by siRNA has shown genuine therapeutic 
potential and opened new horizons in the areas of cancer research, HIV 
treatment, genetic disorders, and pharmaceutical drug development (Jacque et 
al., 2002; Brummelkamp et al., 2003; Dorsett and Tuschl, 2004; Whelan, 2005). 
35 
Aim of Study 
Thus the objective of this study was to utilize RNAi using specific siRNA to 
silence TLR4 or NFATc1 expression in monocytes and osteoclast cells in order 
to modulate the effects of LPS stimulation, and to provide a potential therapeutic 
approach in the field of endodontic research. The specific aims for this study are: 
Specific Aim 1: To examine the efficiency of siRNA transfection in 
monocytes and osteoclasts. 
Specific Aim 2: To examine the expression of TLR4 and NFATc1 levels in 
osteoclast cells transfected with specific siRNA 
Specific Aim 3: To examine the biological effect of the suppression of 
TLR4 and NFATc1 with effective siRNA. The transfected and control cells 
will be stimulated with LPS. The production of cytokines will be examined 
with ELISA and osteoclast formation will be quantitatively analyzed. 
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Material and Methods 
Preparation of Osteoclasts 
Osteoclast-like cells (OCl) were differentiated from RAW 264.7 cells, a 
mouse hematopoietic cell line (American Type Culture collection, Rockville, MD). 
For morphological examination, RAW 264.7 cells were plated at a density of 
40,000 cells/well in 24 well plates in alpha modified Eagle medium with 10% fetal 
bovine serum (Invitrogen, Carlsbad, California). The cells were incubated at 
37°C in a humidified atmosphere containing 5% CO2. 
TRAP Assay 
Tartrate resistant acid phosphatase (TRAP) is a marker enzyme specific 
for osteoclasts. At 96 h of culture, cells were fixed with 2% paraformaldehyde, 
washed with phosphate buffered saline, and treated for 20 minutes with 0.2% 
Triton X-100 solution to permeabilize cell membranes. Cytochemical staining of 
tartrate-resistant acid phosphatase (TRAP)-positive cells was performed as 
described previously (Holliday et a/., 2003). TRAP-positive cells appeared dark 
red. Only TRAP-positive cells with more than 3 nuclei were counted. The values 
are expressed as means ± SE of triplicate cultures. 
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RNA Extraction, Quantification, and Reverse Transcription 
Total RNA was extracted using TRIZOL reagent (Invitrogen) and 
phenol/choloroform according to manufacturer's instructions. RNA was dissolved 
in Tris-EDTA (TE), PH 7.4 and the concentration of RNA was determined by 
measuring the spectrophotometric absorbance at 260 nm. The concentration of 
extracted RNA was 0.5 I-Ig/I-II-1 I-Ig/I-II. RNA was treated with DNAse I (Invitrogen) 
for 15 minutes followed by DNase I inactivation with 25 mM EDTA at 65°C to 
remove genomic DNA contamination. Reverse transcription was carried out in a 
20 1-11 volume containing about 3 I-Ig of RNA, 11-11 of 50 ng/I-II random hexamers 
and 1 IJI annealing buffer, 10 1-11 2X first-strand reaction mix and 2 1-11 superscript 
III/RNase OUT enzyme mix (Invitrogen) at 25°C for 10 minutes and then at 50°C 
for 50 minutes. 
Real-time peR 
Taqman real-time PCR was performed from 1 1-11 of cDNA using TaqMan 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA) with 100-nM 
primers and a 50-nM probe. The Taqman Real-time RT-PCR was performed on 
a Taqman ABI 7500 sequence Detection System (Applied Biosystems). 
Unlabeled specific primers and the TaqMan MGB probes (6-FAM dye-labeled) 
for detecting the mouse TRAP gene (Assay 10: Mm00475698 m1); calcitonin 
receptor gene (Assay 10: Mm00432271 m1) and cathepsin K gene (Assay 10: 
Mm00484036 m1) were used. A Taqman eukaryotic 18S endogenous control kit 
was used for housekeeping gene control. Cycling conditions were: After an initial 
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hold of 2 minutes at 50°C and 10 minutes at 95°C, the samples were cycled 40 
times at 95°C for 15 seconds and 60°C for 1 minute. Each sample was assayed 
in triplicate. 
Traditional PCR used to analyze the amount of PCR product at the end of 
the reaction does not truly represent the initial amount of starting material 
whereas real-time PCR monitors the amount of amplicon in the reaction as it is 
produced during each PCR cycle. As a result, real-time PCR methodology 
provides fast, precise, and accurate results by monitoring the amplification of 
products during the reaction and allows quantification of rare transcripts and 
small changes in gene expression. The Taqman technique is most widely used 
for real-time PCR detection techniques. It uses the 5'-3' exonuclease activity of 
Taq DNA polymerase to cleave a dual-labeled probe annealed to the target 
sequence during PCR amplification. The probe, a sequence complementary to 
the mRNA located between the forward and reverse primers, contains both a 
fluorescent reporter dye at the 5'-end and a quencher dye at the 3'-end. The 
fluorescent emission activity of the reporter dye is neutralized by a quenching 
dye when the TaqMan probe is hybridized to its target sequence. During PCR 
amplification, Taq DNA polymerase cleaves the TaqMan probe into fragments 
through its 5'-3' endonucleolytic activity. Thus the reporter dye is separated from 
the quenching dye, resulting in an increase in fluorescence that is directly 
proportional to the amplification of the molecule. Applied Biosystem has 
commercially available fluorescence-labeled primers and probes for mouse 
osteoclast-specific genes and endogenous control gene 185 ribosomal RNA. 
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Real-time PCR is currently considered the gold standard for quantitative 
measurement of mRNA, having both high sensitivity and specificity. 
Statistical Analysis of Ct Comparative Gene Expression 
The comparative Ct method was applied to determine comparative 
expression levels between samples relative to control gene expression. To 
examine regulation by NFATc1-specific or TLR4-specific siRNA, the amplification 
threshold cycle value (Ct) from each treated sample was subtracted from the 
control-treated sample cycle values (ACt=Ct control-Ct treated). The ratio was 
obtained by calculating the values obtained for gene of interest and the house-
keeping gene 18S rRNA. The fold change of the test gene was determined as 
2(L'lCI gene- L'I ct 185). 
Data are expressed as mean values ± SEM. Statistical significance of 
differences was determined by one way ANOVA and followed by posthoc test 
(Fisher's protected least significant difference (PLSD). Differences were 
considered statistically significant at P < 0.05. 
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siRNA Transfection 
TLR4 or NFATc1 were silenced by using TLR4 or NFATc1 SMARTPOOL 
small interfering RNA (siRNA) reagent (Dharm), respectively. 
For osteoclast examination, RANKL-stimulated RAW 264.7 cells on glass 
coverslips in 24-well plates for first 24 h were either not transfected or transfected 
using 1.5 U control or effective siRNA and 1.5 U fluorescent double-stranded 
RNA (Dharham) combined with 2 1-11 lipofectamine 2000 (Invitrogen) in Opti-MEM 
media supplemented. Six hours after transfection, the media was replaced by 
aMEM with fetal bovine serum (FBS) and 100 ng/ml LPS. No antibiotics were 
used. The cells were incubated for 30 h at 3rC in a CO2 incubator for additional 
4 days after which they were fixed in 2% paraformaldehyde. The nuclei were 
then counterstained with a DAPI stain, which binds the nucleotides, in order to 
visualize the relative location of the siRNA. Only cells with uptake of the 
fluorescent oligomer (FITC) by fluorescent microscopy were identified as having 
the control siRNA. 
For assessment of cytokine expression, RAW264.7 cells were plated on 
24-well plates with DMEM and 10% FCS at density 40,000/well for 24 h. Cells 
were then either not transfected or transfected using 1.5 U control or 
experimental siRNA and 1.5 U fluorescent oligomer combined with 2 1-11 
lipofectamine 2000. Six hours after transfection, the media was replaced by 
DMEM with FBS. The cells were incubated at 3rC in a CO2 incubator for an 
additional 3 days. During the last 24 h of culture, cells were stimulated with 100 
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ng/ml LPS. The medium were collected and stored in -70°C for ELISA analysis. 
RNA was extracted for real-time PCR assay. 
ELISA 
Concentrations of IL-1, IL-6, and TNFa in culture supernatants were 
determined by ELISA in triplicate with commercial ELISA Duo systems (R&D 
systems), according to the respective manufacturer's instructions. For each 
sample and assay, the mean of the triplicate measurement were calculated. 
Immunostaining and Microscopy 
Marrow osteoclasts or RAW 264.7-derived osteoclast-like cells were fixed 
in 2% formaldehyde in PBS on ice for 20 minutes. Osteoclasts were detergent-
permeabilized with 0.2% Triton X-100 in PBS for 10 minutes, washed, and 
blocked in PBS with 2% bovine serum albumin (BSA) for 2 h. The cells were 
stained with rhodamine-phalloidin or antibodies recognizing TLR4, NFATc1 at a 
dilution of 1: 1 00 in PBS. Secondary antibodies were diluted according to the 
manufacturer's instructions. 
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Results 
Evaluation of siRNA Transfection in Monocytes 
Traditionally, it is difficult to manipulate gene expression in monocytes and 
especially osteoclasts, because they are terminally differentiated cells. Monocyte 
cells were transfected with a fluorescently labeled control siRNA using a 
commercially available lipfectamine kit and visualized by fluorescence 
microscopy 72 hours post transfection (Figure 9). The nuclei were 
counterstained with a DAPI stain, which binds the nucleotides in order to 
visualize the relative location of the siRNA (Figure 10). 
Figure 9. Monocytes transfected with 
control fluorescent-labeled siRNA and 
visualized by fluorescence microscopy. 
Figure 10. Monocyte nuclei stained with 
DAPI. 
When the two images above are superimposed, we see the red dots around the 
nuclei, which indicates that the siRNA are delivered into the cytoplasm with high 
efficency (Figure 11). 
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Figure 11. SiRNA are delivered mainly to the cytoplasm with 
high efficency. 
Evaluation of siRNA Transfection in Osteoclast-like cells 
Similarly, we used osteoclast-like cells that were differentiated using LPS 
or RANKL and tranfected them with fluorescent-labeled siRNA (Figure 12) and 
the nuclei were stained with DAPI (Figure 13). 
Figure 12. Osteoclast-like cells 
transfected with fluorescent-labeled 
siRNA. 
Figure 13. Osteoclast nuclei stained with 
DAPI. 
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When the two images above are superimposed, we see that osteoclasts are 
multinucleated (as indicated by the blue dots) and the fluorescent-labeled siRNA 
are highly concentrated in the peripheral cytoplasm around the nucleus. 
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Figure 14. SiRNA are delivered mainly to the cytoplasm of 
osteoclasts with high efficiency. 
When we stained with TRAP, which is a purple stain and marker for osteoclast 
identification, we see TRAP+ cells that are phenotypically identical to 
untransfected osteoclasts (Figure 15). 
Figure 15. Osteoclasts transfected with siRNA appear 
phenotypically identical to untransfected osteoclasts. 
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Silencing NFATc1 Expression in Osteoclasts with siRNA 
In the next step, we examined the efficacy of siRNA in silencing NFATc1 
protein expression. In the control group, osteoclast cells were transfected with 
control siRNA and immunocytologically stained with anti-NFATc1 antibody. This 
method locates NFATc1 protein expression inside the cell. We observed intense 
nuclear accumulation of NFATc1 protein in osteoclasts which was to be 
expected, as NFATc1 is a transcription factor and therefore should be located in 
the nucleus (Figure 16). In the experimental group, osteoclasts were transfected 
with NFATc1-specific siRNA and similarly stained witl, anti-NFATc1 antibody. 
We observed a significant reduction of NFATc1 protein expression in the nucleus 
as compared to the control (Figure 17). 
Figure 16. Osteoclasts transfected with 
control siRNA show intense nuclear 
accumulation of NFATc1 protein (arrows). 
Figure 17. Osteoclasts transfected with 
NFATc1 show a significant reduction of 
NFA Tc1 protein in the nucleus (arrows). 
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When the nuclei were counterstained with DAPI and the images were 
superimposed, we can better appreciate that the nuclei are still present in both 
groups, even though there was reduced NFATc1 protein expression in the 
experimental group (Figure 18). 
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Control siRNA NFATc1 siRNA 
Figure 18. Nuclear staining with DAPI reveals that nuclei are still present in both the 
control and experimental groups. 
This indicates that we were able to partially silence the expression of NFAT c1 in 
osteoclasts using NFATc1-specific siRNA. 
Silencing TLR4 Expression in Osteoclasts with siRNA 
Similarly, we examined the efficacy of siRNA in silencing TLR4 protein 
expression. In the control group, osteoclast cells were transfected with control 
siRNA and immunocytologically stained with anti-TLR4 antibody (Figure 19). In 
the experimental group, osteoclasts were transfected with TLR4-specific siRNA 
and also stained with anti-TLR4 antibody. We observed a significant reduction in 
TLR4 expression on the cell surface as compared to the control (Figure 20). 
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Figure 19. Osteoclasts transfected with 
control siRNA and stained with Anti-
TLR4 antibody. 
Figure 20. Osteoclasts transfected with 
TLR4-specific siRNA and stained with 
Anti-TLR4 antibody. 
When the nuclei were counterstained with DAPI and the two images 
superimposed, we can see that the nuclei are unaffected in both groups, even 
though there is reduced TLR4 protein expression in the experimental group 
(Figure 21). 
Control siRNA TLR4siRNA 
Figure 21. Nuclear staining with DAPI reveals that nuclei are still present in both the control 
and experimental groups. 
This indicates that we were also able to partially silence the expression of TLR4 
in osteoclasts using TLR4 specific siRNA. 
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Biological Effects of Silencing NFATc1 or TLR4 Expression in Monocytes 
Since monocytes are the predominant producers of cytokines in response 
to LPS stimulation, we then examined what effect silencing NFATc1 or TLR4 
expression would have on TNF-a, IL-6, and IL-1 production. Monocytes were 
transfected with either N FAT c1-specific, TLR4-specific, or control siRNA and the 
cells were stimulated with LPS. Media was collected after 24 hours and 
analyzed for cytokine production using ELISA. Results are shown in Table 1. 
Analysis of Variance revealed cells in both the NFATc1-specific and TLR4-
specific siRNA groups showed a statistically significant resistance to LPS 
stimulation as indicated by the down regulated TNF-a and IL-6 levels compared 
with that in the control siRNA group (p<O.05) (Figure 22). There was no 
statistical significance between the NFATc1-specific or TLR4-specific siRNA 
groups for TNF-a or IL-6 production. There also was no significant difference 
between or among the control, NFAT-c1, or TLR4 siRNA groups when analyzed 
for IL-1 production. 
Monocyte Cytokine Production 
IL-6 ELISA (measured in ng/ml) 
NOLPS LPS+control siRNA LPS + TLR4 siRNA LPS +NFATc1 siRNA 
Not detectable 9.52 +/-2.05 *3.48 +/-0.78 *5.11 +/-0.98 
TNF-alpha ELISA (measured in ng/ml) 
Not detecatble 23.49 +1-0.98 *15.17 +/-1.01 *18.31 +/-1.43 
IL-1 alpha ELISA (measured in pg/ml) 
Not detectable 30.7 +/-3.2 25.7 +/-3.8 32.7 +/-2.5 
Table 1. Biological effects of silencing NFATc1 or TLR4 on monocyte cytokine production 
*denotes statistical Significance relative to control, P<O.OS. (Data obtained from an 
average of 3 trials) 
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Figure 22. Inhibition of cytokine release in monocytes mediated by 
siRNA. * denotes statistical significance relative to control, P<O.05. 
Biological Effects of Silencing NFATc1 or TLR4 Expression on Osteoclast 
Formation 
Monocytes were stimulated with RANKL for 24 hours and then transfected 
with either NFATc1-specific, TLR4-specific, or control siRNA. Cells were then 
stimulated with LPS for an additional 72 hours. TRAP+ cells with more than 
three nuclei were counted. Results are shown in Table 2. 
Number of Osteoclasts Formed 
IControl siRNA I TLR4 siRNA I NFATc1 siRNA I 
I 356 +/-25 I *234 +/-58 I *152 +/-39 I 
Table 2. Biological effects of silencing NFA Tc1 or TLR4 on osteoclast 
formation. *denotes statistical significance relative to control, P<O.05. 
(Data obtained from an average of 3 trials) 
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Analysis of Variance revealed a statistically significant fewer number of 
osteoclasts formed in cultures treated with NFATc1 or TLR4-specific siRNA as 
compared with that in the control siRNA group (P<O.05) (Figures 23 and 24). 
There was no statistical significance between the NFATc1 or TLR4-specific 
siRNA groups with respect to the number of osteoclasts formed. 
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Figure 23. Inhibtion of osteoclast formation mediated by siRNA. *denotes statistical 
significance relative to control, P<0.05. 
Cultures transfected with control siRNA 
Figure 24. 
Cultures transfected with either NFATc1 or 
TLR4 siRNA. 
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Biological Effects of Silencing NFATc1 or TLR4 Expression on Osteoclast-
Specific Gene Expression 
Osteoclast-like cells were differentiated using LPS or RANKL and 
tranfected with either NFATc1-specific, TLR4-specific, or control siRNA. Cells 
were then stimulated with LPS for an additional 72 hours. RNA was extracted 
and reverse transcribed into cDNA and Real time PCR (RT PCR) was performed 
to determine comparative mRNA expression levels of cathepsin K, tartrate-
resistant acid phosphatase (TRAP), IL-6, and TNF-a relative to control gene 
expression. The relative expression fold change determined from the application 
curve of RT PCR revealed a statistically significant decrease of cathepsin K, 
TRAP, IL-6, and TNF-a mRNA levels in osteoclasts treated with NFATc1 or 
TLR4-specific siRNA as compared with that in the control siRNA group (P<O.05) 
(Figure 25). There was no statistical significance between the NFATc1 or TLR4-
specific siRNA groups with respect to mRNA expression levels. 
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Figure 25. Inhibition of osteoclast mRNA expression mediated by siRNA. *denotes statistical 
significance relative to control, P<O.05. 
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Biogical Effects of Silencing NFATc1 or TLR4 Expression on Osteoclast 
TNF-a Production 
Osteoclast-like cells were differentiated using LPS or RANKL and 
tranfected with either NFATc1-specific, TLR4-specific, or control siRNA. Cells 
were then stimulated with LPS for an additional 72 hours. Media was collected 
and analyzed for TNF-a cytokine production using ELISA. Results are shown in 
Table 3. 
Osteoclast TNF-alpha Production 
Control siRNA TLR4siRNA NFATc1 siRNA 
3.8 ng/ml +1-0.29 *2.6 ng/ml +1-0.32 *1.88 ng/ml +/-0.14 
Table 3. Biological effects of silencing NFATc1 or TLR4 on osteoclast TNF-a production. 
*denotes statistical significance relative to control, P<O.05. (Data obtained from an average 
of 3 trials) 
Analysis of Variance revealed osteoclasts in both the NFATc1-specific and 
TLR4-specific siRNA groups showed a statistically significant resistance to LPS 
stimulation as indicated by the reduced TNF-a production compared with that in 
the control siRNA group (p<O.05) (Figure 26). There was no statistical 
significance between the NFATc1-specific or TLR4-specific siRNA groups for 
TNF-a production. 
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Figure 26. Inhibition of TNF-a production in osteoclasts mediated by siRNA. *denotes 
statistical significance relative to control, P<0.05. 
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Discussion 
RNA interference is a conserved biologic response by which dsRNA 
induces the sequence-specific degradation of complementary mRNA, thereby 
silencing target gene expression. It has rapidly become the method of choice for 
studies of gene function and gene silencing experiments. We chose to 
independently suppress the expression of two different proteins involved in the 
mechanism of cytokine production and osteoclast formation. Toll-like receptors 
are a newly discovered class of trans-membrane receptors found on the surface 
of immune cells, whose activation has been shown to be critical for the initiation 
of inflammatory reactions induced by bacterial byproducts. TLR4 is the 
established receptor for LPS, which is an integral component of the cell wall of 
gram-negative bacteria found in the root canals of infected teeth. The 
relationship between LPS and periapical bone resorption has been well 
documented in endodontic literature. Previous studies have demonstrated the 
mechanisms by which LPS stimulates osteoblasts and surrounding cells to 
secrete pro-inflammatory cytokines such as TNF-a and IL-6 that are responsible 
for bone resorptive activity (Nair, 1996). More recent findings have shown that 
LPS can directly stimulate osteoblasts through NF-KB activation of target genes 
to express RANKL, which results in the induction of osteoclast formation (Kikuchi 
et al., 2001). Our group was able to demonstrate that LPS can directly induce 
monocytes to differentiate into mature osteoclasts through a shared mechanism, 
yet independent from the RANK-RANKL interaction (Jiang et al., 2006). NFATc1 
is the most strongly induced transcription factor gene mediated by RANKL 
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stimulation whose presence has been shown to be required during the final stage 
of osteoclastogenesis. 
It has been previously demonstrated that antisense sequence targeting of 
TLR4 inhibited TLR4 expression and reduced TNF-a release when RAW 264.7 
cells were stimulated by LPS (Li et al., 2004). Our ability to successfully transfect 
and silence TLR4 and NFATc1 gene expression with specific siRNA in 
monocytes resulted in a significant reduction of LPS-induced TNF-a and IL-6 
production and fewer numbers of mature osteoclasts formed. We did not observe 
a difference in IL-1 production, but that may be due to the fact that monocytes 
produce very low levels of IL-1 to begin with, as was demonstrated in the control 
group. We also showed that successful transfection of osteoclasts with TLR4 or 
NFATc1-specific siRNA resulted in a significant reduction of osteoclast specific 
gene expression and lower levels of TNF-a production. Further studies using 
RNAi in animal models need to be conducted in order to observe the therapeutic 
relevance in treatment of endodontic disease. 
There are two reasons that can account for the fact that we did not obtain 
100% silencing of the gene products observed: 1) This technique only blocks the 
expression of newly transcribed mRNA, and the observed levels may be due to 
residual proteins expressed by the cells prior to siRNA transfection and 2) 
background from mRNA or protein present in cells that were not successfully 
transfected will make the knockdown appear less effective than it actually is 
(Zhou et al., 2006). Nonetheless, this demonstrates the potential that RNAi may 
have as a novel therapeutic strategy in treating endodontic disease. 
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Several other approaches have been used in the past which utilize 
sequence homology for the targeted inhibition of gene expression. These 
include Homologous Recombination, Antisense Vectors, and catalytic DNA 
molecules (DNAzymes) (Capecchi, 1989; Scherer and Rossi, 2003). However, 
due to their limited cross-species application, none show to be as promising as 
RNAi (Opalinska and Gewirtz, 2002). 
Currently, RNAi is most commonly used as a rapid and accurate tool for 
identification of gene function. Many researchers have employed this technology 
to elucidate the roles of individual genes in regulating cell growth, differentiation, 
and survival in a broad range of cell lines (Klampfer et al., 2004; Yin et al., 2004). 
Other groups have deployed RNAi for the identification of potential drug targets 
by determining gene function and linking it to specific diseases (Nencioni et al., 
2004). This process is known as drug target discovery. These types of studies 
represent a powerful approach for the identification of new drug target sites by 
identifying a potential therapeutic target and verifying the desired effect of that 
target upon regulation. RNAi has also been used to dissect cellular signal 
transduction pathways. Cells treated with siRNA targeting a given gene can then 
be monitored using a microarray for the expression of other genes. Sequential 
targeting of various genes with siRNA makes it possible to identify genes that are 
associated with the target and to locate the position of each gene in a given 
pathway. This technology has been successfully used in determining gene 
function in the transforming growth factor beta (TGF-~) pathway, mitogenic 
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signaling pathway in osteoblasts, and insulin signaling (Levy and Hill, 2005; 
Miguel et al., 2005; Shyu et al., 2005). 
However, the greatest promise for RNAi may be in the field of clinical 
medicine, and its potential for therapy against a broad range of diseases. 
Preliminary studies using siRNA to specifically target the HIV structural proteins 
Gag and Env, the regulatory proteins Tat and Rev, the two accessory proteins 
Nef and Vif, the Pol enzymes, or the viral RNA sequences in the long terminal 
repeat (L TR) domain have been shown to potently inhibit HIV-1 replication in 
human T cell lines (Jacque et al., 2002; Novina et al., 2002). In addition to 
targeting of the viral RNA, others have sought to inhbit viral replication using 
RNAi by silencing host cell receptors such as CD4, CXCR4, and CCR5 which are 
essential for attachment and subsequent entry of the HIV-1 virus into the host 
(Martinez et al., 2002a). 
Although the majority of studies on RNAi-mediated inhibition of infectious 
viral diseases have focused on HIV, inhibition of viral replication by RNAi has 
been demonstrated in vitro for a number of other RNA viruses including hepatitis 
C (HCV), poliovirus, Rous sarcoma virus (RSV), rhesus rotavirus (RRV), 
influenza virus, respiratory syncytial virus, dengue virus, coronavirus, as well as 
DNA viruses such as human papillomavirus type 16 (HPV-16), hepatitis B (HBV), 
and herpes simplex virus (Gitlin and Andino, 2003; Lieberman et al., 2003). 
For chronic liver inflammatory diseases such as hepatitis B and hepatitis 
C, researchers have used synthetic siRNAs to target against sequences 
responsible for transciption and protein-coding regions of the capsid (Kapadia et 
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aI., 2003; Shlomai et al., 2003). Their results found up to a 100-fold inhibition for 
HCV capsid proteins and a 6-fold decrease in secreted HBV surface antigen in 
the serum. HBV is the first virus whose inhibition was demonstrated in vivo using 
an animal model (McCaffrey et al., 2003). Thus, experimental data strongly 
support a role for the therapeutic potential of RNAi in the treatment of HBV and 
HCV infections. 
The Influenza and respiratory syncytial viruses are major causes of 
infection of the respiratory tract in humans. Several groups have demonstrated 
that synthetic siRNA targeting conserved regions of the genome, when 
administered by intravenous injection or via intranasal routes, could effectively 
inhibit virus production (Ge et al., 2004; Bitko et al., 2005; Zhang et al., 2005). 
Severe acute respiratory syndrome (SARS) is a viral respiratory illness that was 
first reported in Asia in February 2003 and within a few months spread to more 
than two dozen countries in North America, South America, Europe, and Asia. 
According to the World Health Organization (WHO), a total of 8,098 people 
worldwide became sick and 774 died. A recent study has reported the use of 
siRNAs in prophylactic and therapeutic regimens targeting the SARS coronavirus 
(SCV) in a Rhesus macaque model (Li et al., 2005a). Their analysis revealed that 
siRNAs significantly reduced SARS-like symptoms, diminished SCV viral levels, 
and reduced alveoli damage without any evidence of siRNA-induced toxicity. 
Currently, there is growing enthusiasm regarding the potential therapeutic 
applications of RNAi for cancer. Most human tumors arise from genetic mutations 
in genes that encode for proteins regulating cell division, which results in 
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uncontrolled cellular growth and differentiation. Thus, the ability to target the 
mutant gene and selectively down regulate expression of abnormal proteins 
without affecting the wild-type counterpart provides an attractive and promising 
tool in gene therapy. Multiple groups have successfully demonstrated siRNA-
induced silencing of cancer-associated genes in vitro. Mutations of the ras 
protooncogene are present in a variety of cancers. One study showed the ability 
to specifically silence the mutant ras oncogene without affecting the wild-type 
copy (Brummelkamp and Bernards, 2003). Other preclinical studies have shown 
growth inhibition and apoptosis of cancer cells by RNAi-mediated suppression of 
various critical oncogenes or tumor-promoting genes, such as vascular 
endothelial growth factor (VEGF), human telomerase (hTR), viral oncogenes 
(HPV E6), or translocated oncogenes (bcr-abl) (Butz et al., 2003; Kosciolek et al., 
2003; Scherr et al., 2003; Zhang et al., 2003). Various other in vivo studies have 
also effectively utilized RNAi in cases of brain, breast, and ovarian cancer to 
reduce tumor formation in animal models (Menendez et a/., 2004; Boado, 2005; 
Onodera et al., 2005). 
However, similar to other forms of gene-based therapies, there are several 
problems associated with the development of siRNA therapeutics. The primary 
obstacle is the in vivo delivery of these small molecules to the desired cell type, 
tissue, or organ. Because of their relatively large molecular mass and high 
negative charge, RNAs have difficulty crossing the cell membrane on their own. 
Two different approaches have been developed to address this concern-1) 
direct introduction of chemically modified synthetic siRNAs enhanced for 
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improved pharmacokinetic properties or 2) the use of plasmid or viral vectors 
containing DNA templates to express siRNA within cells. 
Synthetic siRNAs may best be suited for short-term interventions and in 
situations in which long-term silencing is not necessary, such as in treatment of 
acute viral infections or silencing of pro-inflammatory host molecules in order to 
prevent tissue damage (Le. apical periodontitis). In cells that are terminally 
differentiated or slow to divide, such as macrophages or osteoclasts, gene 
suppression by exogenously administered synthetic siRNA can last up to several 
weeks, yet their effect in cells that undergo rapid division is more short-lived 
(peaking within 2-3 days, and gone by 1 week), as a result of continuous dilution 
of the siRNA with each cell division (Song at a/., 2003). However, the half-life of 
unmodified siRNAs in serum is very short (reports vary from minutes to days), 
and their cellular uptake is not ideal. The short half-life is primarily due to their 
rapid elimination by renal filtration due to their small size (-7kDa) and 
degradation by endogenous ribonuclease digestion. Thus, the bioavailability of 
unmodified siRNAs is limited under characteristic in vivo conditions, and gene 
silencing levels are likely to be insignificant. For this reason, numerous attempts 
have been made to chemically modify siRNAs in order to decrease their 
susceptibility to serum nuclease attack without sacrificing biological activity, 
allowing them to maintain sufficient gene-silencing activity for therapeutic use 
(Amarzguioui at a/., 2003; Braasch at a/., 2003; Chiu and Rana, 2003). 
Chemical modifications can easily be placed at the terminal ends, within 
the backbone, or at the ribose molecules of the siRNA duplex {de Fougerolles at 
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al., 2005). Particularly, phosphorothioate modification of the internucleoside 
linkage has been shown to improve nuclease stability and is well tolerated within 
the siRNA duplex (Levin, 1999; Harborth et al., 2003). Encapsulation of siRNAs 
in lipid complexes or liposomes, coupling to fusogenic peptides, or linkage to 
antibodies or cell surface receptor ligands may also facilitate better entry into 
cells and improve biodistribution by producing potential drug candidates that are 
big enough to bypass rapid filtration by the kidney (Manoharan, 2002). Recently, 
chemically modified siRNAs covalently linked to cholesterol were shown to 
improve binding to blood components, thereby increasing the circulation time of 
the siRNAs, and increase delivery to hepatocytes (Lorenz et al., 2004; Soutschek 
et al., 2004). A dinitrophenol modification at the terminal ends has been shown 
to improve transfection efficiency and enhance intracellular stability in vitro (Liao 
and Wang, 2005), and perhaps, of most interest to researchers, peptide-
conjugates have shown to improve cell permeation properties as well as 
sequence-specific targeting (Juliano, 2005). However, chemically synthesized 
siRNAs are expensive, which poses some difficulty, when genome-wide RNAi 
screens are considered in mammalian cells. 
In order to circumvent some of the issues involved with direct siRNA 
transfection, several groups have developed vector-based delivery systems that 
mediate the production of stable siRNA-like molecules in mammalian cells 
(Brummelkamp et al., 2002; Paddison et al., 2002; Paul et al., 2002). Viral 
vectors derived from adenovirus, adeno-associated virus, retrovirus, or lentivirus 
can be used for more long-term gene silencing, which would be more effective 
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for the treatment of chronic infections such as HIV or hepatitis C. These vectors 
are engineered to use RNA-polymerase III promoters to direct the synthesis of 
short hairpin RNA (shRNA) molecules, which are intracellularly processed into 
molecules resembling siRNA that are identical in sequence to the mRNA being 
targeted for suppression. Vector-based production of shRNA in vivo have been 
shown to be as effective as in vitro generated synthetic siRNA in suppressing 
gene expression, and, additionally, can be used to observe loss-of-function 
phenotypes that take longer periods of time to develop (Brummelkamp et a/., 
2002a; Rubinson et a/., 2003; Scherr et a/., 2003a). 
Although great progress has been made in the development of gene-
therapy vectors, there are still a number of concerns about safety and control of 
gene expression associated with vector-delivered gene therapy (Thomas et a/., 
2003). These include efficient transduction of targeted cells, sustained and 
efficient gene expression of transduced cells, the danger of malignant 
transformation resulting from insertional mutagenesis, as well as host immune or 
inflammatory responses to the viral vector itself. Furthermore, the effect of long-
term expression of shRNA in mammalian cells is unknown. 
Even though the original studies of siRNA silencing suggested high 
specificity, several mechanisms have been described with both synthetic and 
vector-based siRNA expression that can lead to unintended effects on gene 
expression and other unexpected "side effects", all of which need to be carefully 
considered when developing RNA-based therapies (Jackson et a/., 2003; 
Jackson and Linsley, 2004). One potential complication is that siRNA has the 
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ability to trigger the innate immune system. Induction of an interferon response 
could potentially cause a global and nonspecific suppression of protein 
translation, particularly in highly sensitive reporter cell lines at high 
concentrations of siRNAs (Sledz et al., 2003). However, interferon response is 
typically induced when the double stranded RNA molecule is greater than 30 
base pairs (McManus and Sharp, 2002), which is longer than the 21-23 nt in 
length siRNA used in RNA interference. Another possible source of toxicity 
might come from the recognition and binding of siRNAs by Toll-like receptor 3, 
which is also a pattern recognition receptor found on immune cells. Upon 
recognition of double stranded RNA molecules, TLR 3 triggers a danger signal 
reaction and initiates a pro-inflammatory response (Kariko et al., 2004). Yet, 
chemical modifications of siRNA may be enough to overcome TLR 3 recognition 
and signaling, and fortunately, these problems have not been observed in most 
animal studies. 
Perhaps a more significant problem associated with siRNA is 
unanticipated "off-target" effects resulting from mRNA cleavage or translational 
repression of genes bearing partially complementary sequences to either strand 
of the duplex siRNA. It. was originally believed that siRNA requires almost 
complete homology throughout the length of its sequence with the intended 
mRNA target for effective RNAi to occur. However, it now appears that as few as 
eleven contiguous complementary base pairs of siRNA may be enough to evoke 
the off-target effect of RNAi-mediated silencing (Jackson, 2003). Although short 
stretches of homology are often inevitable, care must be taken to avoid longer 
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stretches which have more considerable effects on gene expression. It is also 
possible, in some cases, for the siRNA sense strand to be preferentially selected 
by the RISC complex instead of the antisense strand, resulting in inhibition of an 
unintended mRNA target (Jackson et al., 2003). However, it may be feasible to 
inhibit activity of the sense strand through chemical modification, while 
maintaining the functionality of the antisense strand, therefore eliminating this 
potential problem (Khvorova et al., 2003; Schwarz et al., 2003; Reynolds et al., 
2004). Furthermore, a recent study found that the majority of off-target effects 
associated with nonspecific silencing of gene expression resulted from the lipid-
based transfection reagent and not the siRNA (Fedorov et al., 2005). This is in 
agreement with others who showed lack of interferon response in mice upon 
injection of naked siRNAs (Heidel et al., 2004). Nonetheless, these issues 
highlight the importance of judicious siRNA design and testing of different 
sequences in order to choose the one with the best target-specific/off-target 
profile. This can be achieved by taking advantage of the wide-ranging databases 
of expressed mRNAs that are currently available. A BLAST search 
(http.1lwww.ncbi.nlm.nih.govIBLASD should be performed to identify the most 
effective siRNA sequences and to make certain that the sequence is homologous 
to the target gene of interest. Additionally, microarray screens should be used to 
monitor genome-wide expression profiles (Clarke et al., 2004). 
Although it is clear that more progress needs to be made to improve 
RNAi-delivery systems and to evaluate off-target effects and other potential 
sources of toxicity, it is encouraging to note that there are more than 30 
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pharmaceutical and biotechnology companies that have stated interest in or 
currently have an RNAi-based drug development program in progress, and many 
have published preliminary data obtained from in vivo and mammalian model 
systems validating their projects. Sirna Therapeutics recently completed a Phase 
I study of Sirna-027, which is a chemically modified siRNA drug that targets 
VEGFR1 in order to treat age-related macular degeneration (AMD), results from 
which were reported at the American Society of Gene Therapy conference in 
June 2005 (Whelan, 2005). They have also collaborated with Protiva 
Biotherapeutics for work relating to treatment of hepatitis B infection (Morrissey 
et al., 2005; Morrissey et al., 2005b). Alnylam Pharmaceuticals has partnered 
with Norvartis, Merck, and Medtronic for drug development projects targeting 
multiple diseases, and has published preliminary results using anti-ApoB siRNAs 
for treatment of hypercholesterolemia (Soutschek et al., 2004). Their next target 
is pandemic influenza, for which they filed an Investigational New Drug 
Application (IND) with the Food and Drug Administration (FDA) in 2006. Nastech 
Pharmaceuticals, working in conjunction with the Mayo Clinic, presented 
preclinical results at the November 2005 American College of Rheumatology 
meeting on the use of an anti-TNF-a siRNA for treatment of rheumatoid arthritis 
(Behlke, 2006). Calando Pharmaceuticals has collaborated with the Children's 
Hospital of Los Angeles to describe the use of siRNA to treat Ewing's sarcoma 
(Hu-Lieskovan et al., 2005). Numerous studies have been published by 
Intradigm, in collaboration with other pharmaceutical companies, using siRNA to 
treat cancer, arthritis, ocular, and viral diseases (Kim et al., 2004; Schiffelers et 
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al., 2004; Li et al., 2005; Schiffelers et al., 2005; Schiffelers et al., 2005b), and 
Abbott and NeoPharm have both investigated the potential of siRNA-based 
therapeutics in a murine cancer model system (Li et al., 2005; Pal et al., 2005). 
However, it should be noted that Fomiversen (Vitravene) manufactured by ISIS 
Pharmaceuticals, which is a drug for the treatment of CMV retinitis, is the only 
existing FDA-approved siRNA-based drug available on the market at this time. 
Not enough may be known about the potential negative effects of 
prolonged or repetitive use of RNAi on normal cellular metabolism when used for 
treatment of chronic diseases. It is possible that toxicities may not show up for 
months, or perhaps years. Clearly, such issues require further long-term studies 
in therapeutically relevant animal models of RNA interference. Nonetheless, 
considering the immense interest and the rapid pace by which RNAi research is 
advancing, it is foreseeable that this relatively new scientific discovery will have a 
dramatic impact on the development of an innovative and new class of drugs 
whose therapeutic potential seems enormous. 
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Conclusion 
RNA interference is a unique and powerful tool that can be used for the 
study gene function by suppressing its expression. It is also a fast and 
inexpensive method to selectively silence a gene product in complex biological 
systems whose clinical potential for treatment of various diseases and disorders 
has been demonstrated. Using RNAi, with specific NFATc1 and TLR4 siRNA we 
were able to successfully: 
1. Deliver siRNA into the cytoplasm of monocytes and osteoclasts 
with high efficiency. 
2. Demonstrate a significant reduction in the expression of TLR4 and 
NFATc1 in cells that were transfected with specific siRNA. 
3. Demonstrate a significant reduction of TNF-a and IL-6 production in 
transfected monocytes in response to LPS stimulation. 
4. Demonstrate a significant reduction in the number of mature 
osteoclasts formed in response to LPS stimulation. 
5. Demonstrate a significant reduction in osteoclast specific gene 
expression and lower levels of TNF-a production in response to 
LPS stimulation. 
Although much work still remains in improving the delivery, specificity, and 
effectiveness of siRNAs, RNAi-based therapies have emerged as highly 
promising prospects with applications for a wide spectrum of diseases. 
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Statistical Analysis 
Oneway analysis of variance for IL-6 ELISA in monocytes 
Descriptives 
Final (uQ/ml) 
95% Confidence Interval 
for Mean 
Std. Std. Lower Upper 
N Mean Deviation Error Bound Bound Minimum Maximum 
control 3 9.52000 2.047144 1.181919 4.43461 14.60539 7.180 10.980 
TLR4 3 3.48000 .784602 .452990 1.53094 5.42906 2.580 4.020 
NFATc1 3 5.11333 .984344 .568311 2.66809 7.55858 4.420 6.240 
Total 9 6.03778 2.960548 .986849 3.76210 8.31346 2.580 10.980 
Test of Homogeneity of Variances 
Final (ug/ml) 
Levene 
Statistic df1 df2 Sig. 
3.246 2 6 .111 
ANOVA 
Final (ug/ml) 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 58.568 2 29.284 15.212 .004 
Within Groups 11.551 6 1.925 
Total 70.119 8 
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Post Hoc Tests for IL-6 production in monocytes 
Multiple Comparisons 
DeDendent Variable: Final (uQ/ml) 
Mean 
Difference 95% Confidence Interval 
(I) LPS + (J) LPS + (I-J) Std. Error Sig. Lower Bound Upper Bound 
Tukey HSD control TLR4 6.040000· 1.132876 .004 2.56403 9.51597 
NFATc1 4.406667· 1.132876 .019 .93069 7.88264 
TLR4 control -6.040000· 1.132876 .004 -9.51597 -2.56403 
NFATc1 -1 .633333 1.132876 .380 -5.10931 1.84264 
NFATc1 control 
-4.406667* 1.132876 .019 -7.88264 -.93069 
TLR4 1.633333 1.132876 .380 -1 .84264 5.10931 
LSD control TLR4 6.040000· 1.132876 .002 3.26795 8.81205 
NFATc1 4.406667· 1.132876 .008 1.63462 7.17871 
TLR4 control -6.040000· 1.132876 .002 -8.81205 -3.26795 
NFATc1 
-1 .633333 1.132876 .199 -4.40538 1.13871 
NFATc1 control -4.406667* 1.132876 .008 -7.17871 -1 .63462 
TLR4 1.633333 1.132876 .199 -1.13871 4.40538 
*. The mean difference is significant at the .05 level. 
Homogeneous Subsets (IL-6 production in monocytes) 
Final (ug/ml) 
Subset for alpha = .05 
LPS + N 1 2 
Tukey Hsoa TLR4 3 3.48000 
NFATc1 3 5.11333 
control 3 9.52000 
Sig. .380 1.000 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 3.000. 
Graph (IL-6 production in monocytes) 
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Oneway analysis of variance TNF - alpha ELISA in monocytes 
Descriptives 
Final (ug/ml\ 
95% Confidence Interval 
for Mean 
Std. Std. Lower Upper 
N Mean Deviation Error Bound Bound Minimum Maximum 
control 3 23.49000 .980064 .565840 21.05539 25.92461 22.695 24.585 
siRNA 
TLR4 3 15.16500 1.005336 .580431 12.66761 17.66239 14.145 16.155 
siRNA 
NFATc1 3 18.31000 1.429047 .825061 14.76005 21.85995 16.725 19.500 
siRNA 
Total 9 18.96633 3.775642 1.256614 16.08596 21.89070 14.145 24.585 
Test of Homogeneity of Variances 
Final (ug/ml) 
Levene 
Statistic df1 df2 Sig. 
.445 2 6 .660 
ANOVA 
Final (ug/ml) 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 106.029 2 53.015 39.628 .000 
Within Groups 8.027 6 1.338 
Total 114.056 8 
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Post Hoc Tests for TNF-alpha production in monocytes 
Multiple Comparisons 
Dependent Variable: Final (ug/ml) 
Mean 
Difference 95% Confidence Interval 
(I) LPS + (J) LPS + (I-J) Std. Error Sig . Lower Bound Upper Bound 
Tukey HSD control siRNA TLR4siRNA 8.325000· .944387 .000 5.42736 11 .22264 
NFATc1 siRNA 5.180000· .944387 .004 2.28236 8.07764 
TLR4 siRNA control siRNA -8.325000· .944387 .000 -11.22264 -5.42736 
NFATc1 siRNA -3.145000· .944387 .036 -6.04264 -.24736 
NFATc1 siRNA control siRNA -5.180000· .944387 .004 -8.07764 -2.28236 
TLR4siRNA 3.145000· .944387 .036 .24736 6.04264 
LSD control siRNA TLR4siRNA 8.325000· .944387 .000 6.01417 10.63583 
NFATc1 siRNA 5.180000· .944387 .002 2.86917 7.49083 
TLR4 siRNA control siRNA -8.325000· .944387 .000 -10.63583 -6.01417 
NFATc1 siRNA -3.145000· .944387 .016 -5.45583 -.83417 
NFATc1 siRNA control siRNA -5.180000· .944387 .002 -7.49083 -2.86917 
TLR4siRNA 3.145000· .944387 .016 .83417 5.45583 
• . The mean difference IS Significant at the .05 level. 
Homogeneous Subsets (TNF-alpha production in monocytes) 
Final (ug/ml) 
Subset for alpha = .05 
LPS + N 1 
Tukey HSDa TLR4 siRNA 3 15.16500 
NFATc1 siRNA 3 
control siRNA 3 
Sig. 1.000 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 3.000. 
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Oneway analysis of variance IL-1 alpha ELISA in monocytes 
Descriptives 
Dilution value 
95% Confidence Interval 
for Mean 
Std. Std. Lower Upper 
N Mean Deviation Error Bound Bound Minimum Maximum 
control 3 30.6667 3.21455 1.85592 22.6813 38.6521 27.00 33.00 
siRNA 
TLR4 3 25.6667 3.78594 2.18581 16.2619 35.0715 23.00 30.00 
siRNA 
NFATc1 3 32.6667 2.51661 1.45297 26.4151 38.9183 30.00 35.00 
siRNA 
Total 9 29.6667 4.18330 1.39443 26.4511 32.8822 23.00 35.00 
Test of Homogeneity of Variances 
Dilution value 
Levene 
Statistic df1 df2 Sig. 
.589 2 6 .584 
ANOVA 
Dilution value 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 78.000 2 39.000 3.774 .087 
Within Groups 62.000 6 10.333 
Total 140.000 8 
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Post Hoc Tests for IL-1-alpha production in monocytes 
Multiple Comparisons 
Dependent Variable: Dilution value 
Mean 
Difference 95% Confidence Interval 
(I) LPS + (J) LPS + (I-J) Std. Error Sig. Lower Bound U~er Bound 
Tukey HSD control siRNA TLR4 siRNA 5.00000 2.62467 .217 -3.0532 13.0532 
NFATc1 siRNA 
-2.00000 2.62467 .738 -1 0.0532 6.0532 
TLR4 siRNA control siRNA 
-5.00000 2.62467 .217 -13.0532 3.0532 
NFATc1 siRNA 
-7.00000 2.62467 .083 -15.0532 1.0532 
NFATc1 siRNA control siRNA 2.00000 2.62467 .738 -6.0532 10.0532 
TLR4 siRNA 7.00000 2.62467 .083 -1.0532 15.0532 
LSD control siRNA TLR4 siRNA 5.00000 2.62467 .105 -1.4223 11.4223 
NFATc1 siRNA -2.00000 2.62467 .475 -8.4223 4.4223 
TLR4 siRNA control siRNA 
-5.00000 2.62467 .105 -11.4223 1.4223 
NFATc1 siRNA 
-7.00000' 2.62467 .037 -13.4223 -.5777 
NFATc1 siRNA control siRNA 2.00000 2.62467 .475 -4.4223 8.4223 
TLR4 siRNA 7.00000' 2.62467 .037 .5777 13.4223 
'. The mean difference IS Significant at the .05 level. 
Homogeneous Subsets (IL-1-alpha production in monocytes) 
Dilution value 
Subset 
for alpha 
= .05 
LPS + N 1 
Tukey Hsoa TLR4 siRNA 3 25.6667 
control siRNA 3 30.6667 
NFATc1 siRNA 3 32.6667 
Sig. .083 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 3.000. 
Graph (IL-1-alpha production in monocytes) 
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Oneway - Number of Osteoclasts Formed 
Oescriptives 
Osteoclasts formed 
95% Confidence Interval for 
Std. Mean 
N Mean Deviation Std. Error Lower Bound Upper Bound Minimum Maximum 
control siRNA 3 356.0000 24.87971 14.36431 294.1954 417.8046 329.00 378.00 
TLR4 siRNA 3 234.0000 57.88782 33.42155 90.1987 377.8013 188.00 299.00 
NFATcl siRNA 3 152.0000 39.00000 22.51666 55.1186 248.8814 128.00 197.00 
Total 9 247.3333 96.31070 32.10357 173.3024 321.3643 128.00 378.00 
AN OVA 
Osteoclasts formed 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 63224.00 2 31612.000 17.271 .003 
Within Groups 10982.00 6 1830.333 
Total 74206.00 8 
Post Hoc Tests for Number of Osteoclasts Formed 
Multiple Comparisons 
Dependent Variable: Osteoclasts formed 
Mean 
Difference 95% Confidence Interval 
(I) LPS + (J) LPS + (I-J) Std. Error Sig. Lower Bound Upper Bound 
Tukey HSD control siRNA TLR4 siRNA 122.00000' 34.93168 .030 14.8200 229.1800 
NFATcl siRNA 204.00000' 34.93168 .003 96.8200 311.1800 
TLR4 siRNA control siRNA -122.00000' 34.93168 .030 -229.1800 -14.8200 
NFATcl siRNA 82.00000 34.93168 .124 -25.1800 189.1800 
NFATcl siRNA control siRNA -204.00000' 34.93168 .003 -311.1800 -96.8200 
TLR4 siRNA -82.00000 34.93168 .124 -189.1800 25.1800 
LSD control siRNA TLR4 siRNA 122.00000' 34.93168 .013 36.5253 207.4747 
NFATcl siRNA 204.00000' 34.93168 .001 118.5253 289.4747 
TLR4 siRNA control siRNA -122.00000' 34.93168 .013 -207.4747 -36.5253 
NFATcl siRNA 82.00000 34.93168 .057 -3.4747 167.4747 
NFATcl siRNA control siRNA -204.00000' 34.93168 .001 -289.4747 -118.5253 
TLR4 siRNA 
-82.00000 34.93168 .057 -167.4747 3.4747 
'. The mean difference IS significant at the .05 level. 
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Homogeneous Subsets 
Osteoclasts formed 
Subset for alpha = .05 
LPS + N 1 
Tukey HSDs NFATc1 siRNA 3 152.0000 
TLR4 siRNA 3 234.0000 
control siRNA 3 
Sig. .124 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 3.000. 
Oneway - Osteoclast TNF-alpha level 
Descriptives 
TNFalpha levels 
Std. 
2 
356.0000 
1.000 
Mean 
al for 
N Mean Deviation St er Bound 
control siRNA 3 3.8000 .28844 .16653 3.0835 4.5165 
TLR4 siRNA 3 2.6000 .31749 .18330 1.8113 3.3887 
NFATc1 siRNA 3 1.8800 .13856 .08000 1.5358 2.2242 
Total 9 2.7600 .86971 .28990 2.0915 3.4285 
ANOVA 
TNF I h I aipi a eves 
Sum of 
Squares df Mean SQuare F 
Between Groups 5.645 2 2.822 41.669 
Within Groups .406 6 .068 
Total 6.051 8 
Minimum Maximum 
3.48 4.04 
2.24 2.84 
1.80 2.04 
1.80 4.04 
Sig. 
.000 
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Post Hoc Tests for Osteoclast TNF-alpha Production 
Multiple Comparisons 
Dependent Variable: TNFalpha levels 
Mean 
Difference 95% Confidence Interval 
(I) LPS+ (J) LPS + (I.J) Std. Error Sig. Lower Bound 
Tukey HSD control siRNA TLR4siRNA 1.20000' .21250 .003 .5480 
NFATc1 siRNA 1.92000' .21250 .000 1.2680 
TLR4 siRNA control siRNA -1.20000' .21250 .003 ·1.8520 
NFATc1 siRNA .72000' .21250 .034 .0680 
NFATc1 siRNA control siRNA -1.92000' .21250 .000 -2.5720 
TLR4 siRNA -.72000' .21250 .034 -1.3720 
LSD control siRNA TLR4 siRNA 1.20000' .21250 .001 .6800 
NFATc1 siRNA 1.92000' .21250 .000 1.4000 
TLR4 siRNA control siRNA -1.20000' .21250 .001 -1.7200 
NFATc1 siRNA .72000' .21250 .015 .2000 
NFATc1 siRNA control siRNA -1.92000' .21250 .000 ·2.4400 
TLR4 siRNA 
-.72000' .21250 .015 -1.2400 
'. The mean difference IS significant at the .05 level. 
Homogeneous Subsets 
TNFalpha levels 
Subset for alpha = .05 
LPS + N 1 
Tukey HSDa NFATc1 siRNA 3 1.8800 
TLR4 siRNA 3 
control siRNA 3 
Sig. 1.000 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size::: 3.000. 
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Graph (Osteoclast TNF-alpha Production) 
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